Member Info for Amonk84

Nice find Landy

From the chairman of the board at EMQN at his practice in Germany...

“The task of the laboratory service provider in the field of rapidly developing genetics begins at the doctor’s side when he asks the question of the appropriate genetic test at the bedside or during the consultation hours.”

EQNM provide external quality assurance for the NHS labs among others. So for them to release a product specifically for Genedrive is significant. Plus with the chairman pushing for rapid poc, I feel this may be the start of something.

Fingers crossed.

A point raised on LinedIn.

POC testing will be a game changer for countries that don't have the resources that the NHS has for lab testing.

Genedrive now have 2 approved assays for their Genedrive system. They will either build on this or be bought out long before by a major who is already working on assays that can be added to the Genedrive platform.

The potential here is huge.

*peer

Take a look at Dr McDermotts LinkedIn post https://www.linkedin.com/feed/update/urn:li:activity:7221519849179553793/

and read the replies from his piers around the world.

This is the future of poc gene testing.

Indeed Muck,

The relevance of the labs tests will become less when more assays become available creating a plethora of rapid poc pharmacogenomic tests for use with Genedrive. It's the logical evolution of this recommended device.

Dr McDermott & Co highlighting the relevance of new 'Rapid' poc pharmacogenomics

https://www.tandfonline.com/eprint/VTWMIGCYAEISA9ZRSQKX/full?target=10.1080/14622416.2024.2366691

With the NICE guidance and the impending rollout of Genedrive, it's only a matter of time before more assays for more pharmacogenomics requirements start appearing.

Lab tests are the preferred method, I'd imagine because they have more scope and don't cost anything extra as it's their own labs. The key to this, is the time scale for the poc test. This will save lives and must be rolled out asap.

This...

💡 Following release of the NICE - National Institute for Health and Care Excellence guidance this morning, our team at the NHS North West Genomic Medicine Service Alliance are already working with colleagues around the country to support implementation efforts, exploring optimal models of service delivery.

The whole point of their platform is for time sensitive testing. There's a plethora of otc gene lab tests out there but they all take days to turnaround.

I stumbled across GDR late last week through a random post on another board. Glad I looked in here.

The NICE draft recommendation of the Genedrive® CYP2C19-ID Kit is what got me to buy in on Friday.

Having read some more, I’m now convinced that this is going to be a game changer of a share.

The BDD news today has got my head in a spin…

I particularly like how the Genedrive system device is the key here. It’s already getting rolled out steadily with the MT-RNR1assay with staff getting trained. This, to me at least, will trigger those foundations already kitted out with the device to start using CYP2C19-ID, once NICE make it’s official (assuming they do), as it’s a tried and tested system for them.

The numbers in the RNS re the cost of lawsuits doesn’t really give us anything to go off for the US, and I couldn’t find any online to indicate how many lawsuits there were.

I did find an estimate from an NHS newsletter in 2015 stating the MT-RNR1 kit could save the NHS £5m per year through preventing cases of infant deafness. Of the £102m budget that year, this equates to a .0049% saving.

If we apply that percentage to the USA healthcare budget for 2023 of $4.8T, Then the MT-RNR1 kit rolled out in the US could save $235m through prevention. That’s not taking into account the lawsuits.

If GDR can catch the eye of an IDN or two across the pond with the BDD for MT-RNR1 then the Genedrive platform will look that much more appetizing with a second assay available, plus with the NICE recommendation too. Some of the integrated delivery networks (IDNs) in the US have upward of 100 hospitals. Keep in mind that MT-RNR1 has generated over £100K in revenue from just 5 UK hospitals.

I get that there’s quite a few assumptions here and my numbers are very much, finger in the air but I like what I’ve read so far and I’ll be adding a more sizable buy to my holding if I can.

ATB & GL

Watch2, do some research on what? You?

Not wanting to answer my question... answers my question.

I find people who manipulate others to be the lowest of the low. No amount of money or success will ever remove the intrinsic evil that's within people like that.

Okay Watching2, can you give me a valid explanation as to your repeated one liners of hyper enthusiasm?

I can understand positivity for a stock your invested in but yourself and a few others seem a little much.

Genuine question this mate.

Are all these spammers on the payroll of those who took part in the placing and are now trying to keep PI's buying whilst their employers offload for a tidy profit?

I think the board will find some bs investment opportunity that will require a fund raise, further diluting all long-suffering holders.

Can buy again now. Got what they wanted

Stops being taken out with this drop I think. It's NT to buy

We only seem to be giving Savanah less than 30% of the Lekoil repayment and building cash reserves with the rest.

I've started to average down on the off chance to BOD have a something up their sleeves.

I could very well be throwing good money after bad, but I'm willing to take the risk.

It's not gone anywhere, we are receiving it in monthly installments from Lekoil's oil sales. There's US$42,248,833 still left to come.

So we've got approx $1m/month income and an Mcap of $9m. This has got to re-rate soon even if the BOD can't figure out what to do with the cash

Someone's opinions, if not themselves offensive, should not be met with such offensive responses.

Reminds me of a playground, where any differences to the norm get verbally abused and ridiculed.

You should be ashamed of yourselves.

Bullies, f##king hate bullies.